Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Olivier Fernagut

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|February 10, 2012
Links between glucocerebrosidase and alpha-synuclein revealedPierre-Olivier Fernagut
Movement Disorders : Official Journal of the Movement Disorder Society|June 18, 2019
Dopamine and eating behavior disorders in Parkinson's disease: A complex recipePierre-Olivier Fernagut
Parkinsonism & Related Disorders|November 23, 2013
Premotor parkinsonism modelsErwan Bezard, Pierre-Olivier Fernagut
Neurobiology of Disease|October 12, 2004
Alpha-synuclein and transgenic mouse modelsPierre-Olivier Fernagut, Marie-Françoise Chesselet
Movement Disorders : Official Journal of the Movement Disorder Society|May 15, 2019
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate modelQin Li, Pierre-Olivier Fernagut, Erwan Bezard
Journal of Neural Transmission (Vienna, Austria : 1996)|March 8, 2018
Impulse control disorders in Parkinson's diseaseAna Marques, Franck Durif, Pierre-Olivier Fernagut
Neurological Research|May 4, 2011
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acidMartina Fantin, Michele Morari, François Tison, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
In vivo models of multiple system atrophyPierre-Olivier Fernagut, Imad Ghorayeb, Elsa Diguet, et al.
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|January 4, 2006
Genetic mouse models of parkinsonism: strengths and limitationsSheila M Fleming, Pierre-Olivier Fernagut, Marie-Françoise Chesselet
Progress in Neurobiology|March 4, 2014
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?Fares Bassil, Pierre-Olivier Fernagut, Erwan Bezard, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Movement Disorders : Official Journal of the Movement Disorder Society|February 10, 2012
Links between glucocerebrosidase and alpha-synuclein revealedPierre-Olivier Fernagut
Movement Disorders : Official Journal of the Movement Disorder Society|June 18, 2019
Dopamine and eating behavior disorders in Parkinson's disease: A complex recipePierre-Olivier Fernagut
Parkinsonism & Related Disorders|November 23, 2013
Premotor parkinsonism modelsErwan Bezard, Pierre-Olivier Fernagut
Neurobiology of Disease|October 12, 2004
Alpha-synuclein and transgenic mouse modelsPierre-Olivier Fernagut, Marie-Françoise Chesselet
Movement Disorders : Official Journal of the Movement Disorder Society|May 15, 2019
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate modelQin Li, Pierre-Olivier Fernagut, Erwan Bezard
Journal of Neural Transmission (Vienna, Austria : 1996)|March 8, 2018
Impulse control disorders in Parkinson's diseaseAna Marques, Franck Durif, Pierre-Olivier Fernagut
Neurological Research|May 4, 2011
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acidMartina Fantin, Michele Morari, François Tison, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
In vivo models of multiple system atrophyPierre-Olivier Fernagut, Imad Ghorayeb, Elsa Diguet, et al.
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|January 4, 2006
Genetic mouse models of parkinsonism: strengths and limitationsSheila M Fleming, Pierre-Olivier Fernagut, Marie-Françoise Chesselet
Progress in Neurobiology|March 4, 2014
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?Fares Bassil, Pierre-Olivier Fernagut, Erwan Bezard, et al.
Pageof 8